

产品名称：酒石酸卡巴拉汀  
 产品别名：Rivastigmine tartrate

生物活性：									
<b>Description</b>	Rivastigmine tartrate, an cholinesterase inhibitor(IC50= 5.5 uM), inhibits both butyrylcholinesterase and acetylcholinesterase IC50 value: 5.5 uM Target: AChE Rivastigmine is a parasymphathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease. The drug can be administered orally or via a transdermal patch; the latter form reduces the prevalence of side effects, which typically include nausea and vomiting. The drug is eliminated through the urine, and appears to have relatively few drug-drug interactions. Rivastigmine, a cholinesterase inhibitor, inhibits both butyrylcholinesterase and acetylcholinesterase. It is thought to work by inhibiting these cholinesterase enzymes, which would otherwise break down the brain chemical acetylcholine.								
<b>Solvent&amp;Solubility</b>	<b>In Vitro:</b> H <sub>2</sub> O : 50 mg/mL (124.87 mM; Need ultrasonic)								
	<b>Preparing Stock Solutions</b>	<table border="1"> <tr> <td>Solvent</td> <td>Mass</td> </tr> <tr> <td colspan="2">Concentration</td> </tr> </table>	Solvent	Mass	Concentration		<b>1 mg</b>	<b>5 mg</b>	<b>10 mg</b>
		Solvent	Mass						
		Concentration							
1 mM	2.4974 mL	12.4869 mL	24.9738 mL						
5 mM	0.4995 mL	2.4974 mL	4.9948 mL						
10 mM	0.2497 mL	1.2487 mL	2.4974 mL						
<p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液，一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。            储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。</p>									
<b>References</b>	<p>[1]. Kurz A, Farlow M, Lefèvre G. Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review. <i>Int J Clin Pract.</i> 2009 May;63(5):799-805.</p> <p>[2]. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease. <i>Clin Ther.</i> 1998 Jul-Aug;20(4):634-47.</p> <p>[3]. Stryjer R, Ophir D, Bar F et al. Rivastigmine treatment for the prevention of electroconvulsive therapy-induced memory deficits in patients with schizophrenia. <i>Clin Neuropharmacol.</i> 2012 Jul-Aug;35(4):161-4.</p> <p>[4]. Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. <i>J Clin Neurol.</i> 2011 Sep;7(3):137-42.</p>								